Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Rapt Therapeutics Inc. has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 3 distinct examiners and 2 distinct art units. Marcos L Sznaidman is the busiest examiner, with 1 pending office action currently assigned.
The involvement of multiple examiners and art units suggests a range of therapeutic developments within the biotechnology sector. This distribution indicates that the company's innovations are being reviewed by different specialized units. The presence of 3 pending office actions across 2 distinct art units shows some concentration in the technological fields being pursued. However, the use of 3 distinct examiners means that each pending matter is being evaluated by a different individual. This lack of examiner concentration requires a tailored approach for each office action response. The current data reflects a multi-pronged strategy for securing patent protection in the Biotechnology & Pharmaceuticals industry, which may lead to varying prosecution timelines across the portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (67%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SZNAIDMAN, MARCOS L | 1 | 37.4% | +16.1% |
| RAO, PADMAJA S | 1 | 70.7% | +36.8% |
| KENYON, JOHN S | 1 | 79.8% | +18.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18907350 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | SZNAIDMAN, MARCOS L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18907350 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | SZNAIDMAN, MARCOS L | — |
| 18768626 | CRYSTALLINE FORMS OF C-C CHEMOKINE RECEPTOR TYPE 4 ANTAGONIST AND USES THEREOF | RAO, PADMAJA S | — |
| 18737044 | CRYSTALLINE FORMS OF C-C CHEMOKINE RECEPTOR TYPE 4 ANTAGONIST AND USES THEREOF | KENYON, JOHN S | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18907350 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | SZNAIDMAN, MARCOS L | — | §102§112 | Non-Final OA | — | Pending | Oct 04, 2024 |
| 18768626 | CRYSTALLINE FORMS OF C-C CHEMOKINE RECEPTOR TYPE 4 ANTAGONIST AND USES THEREOF | RAO, PADMAJA S | 1627 | §103§112DP | Non-Final OA | — | Pending | Jul 10, 2024 |
| 18737044 | CRYSTALLINE FORMS OF C-C CHEMOKINE RECEPTOR TYPE 4 ANTAGONIST AND USES THEREOF | KENYON, JOHN S | 1625 | §112DP | Non-Final OA | — | Pending | Jun 07, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRapt Therapeutics Inc. has 3 pending office actions as of November 2026, spread across 2 art units and 3 examiners.
Marcos L Sznaidman has the most, with 1 of Rapt Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.